Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Dual silencing of Bcl-2 and Survivin by HSV-1 vector shows better antitumor efficacy in higher PKR phosphorylation tumor cells in vitro and in vivo

Cancer Gene Therapy volume 22, pages 380–386 (2015)Cite this article

Subjects

Abstract

RNA interference (RNAi) is a promising tool for cancer therapy, but its delivery strategy is a major challenge for its application. Oncolytic herpes simplex virus type 1 (HSV-1) is not only an effective antitumor drug but also an excellent vector. Herein, RNAi of oncogenes Bcl-2 and Survivin was combined with oncolytic HSV-1 (ICP34.5-/ICP6-/ICP47-/CMV-GM-CSF) and a new vector HSV010-BS was constructed. Transfected cell viability assays and animal experiments revealed that the dual silencing of Bcl-2 and Survivin improved the antitumor effect of oncolytic HSV-1 in vitro and in vivo, while the antitumor effect was correlated with the phosphorylation levels of PKR of the tumor cells. The higher the phosphorylation levels of PKR of the tumor cells, the weaker the replication ability of oncolytic HSV-1, and the more powerful HSV010-BS was than its control vectors in inhibiting the growth of the tumor cells. The results provided direct supportive proofs for a new potential cancer therapy strategy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu JQ, Ward E . Cancer Statistics, 2010. CA Cancer J Clins 2010; 60: 277–300.

    Article  Google Scholar 

  2. Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL . Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol Ther 2014; 22: 123–131.

    Article  CAS  Google Scholar 

  3. Bourke MG, Salwa S, Harrington KJ, Kucharczyk MJ, Forde PF, Kruijf de M et al. The emerging role of viruses in the treatment of solid tumours. Cancer Treat Rev 2011; 37: 618–632.

    Article  CAS  Google Scholar 

  4. Aghi MK, Chiocca EA . Phase Ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol Ther 2009; 17: 8–9.

    Article  CAS  Google Scholar 

  5. Hu JCC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ et al. A phase I study of OncoVEX(GM-CSF), a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737–6747.

    Article  CAS  Google Scholar 

  6. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763–5771.

    Article  CAS  Google Scholar 

  7. Fu X, Tao L, Rivera A, Zhang X . Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication. Int J Cancer 2010; 129: 1503–1510.

    Article  Google Scholar 

  8. Smith KD, Shao MY, Posner MC, Weichselbaum RR . Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application. Future Oncol 2007; 3: 545–556.

    Article  CAS  Google Scholar 

  9. Campadelli-Fiume G, De Giovanni C, Gatta V, Nanni P, Lollini P-L, Menotti L . Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol 2011; 21: 213–226.

    Article  CAS  Google Scholar 

  10. Smith KD, Mezhir JJ, Bickenbach K, Veerapong J, Charron J, Posner MC et al. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Delta gamma(1)34.5 mutants of herpes simplex virus 1. J Virol 2006; 80: 1110–1120.

    Article  CAS  Google Scholar 

  11. Katze MG . Regulation of the interferon-induced PKR: can viruses cope? Trends Microbiol 1995; 3: 75–78.

    Article  CAS  Google Scholar 

  12. He B, Gross M, Roizman B . The gamma(1)34.5 protein of herpes simplex virus I complexes with protein phosphatase 1 alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997; 94: 843–848.

    Article  CAS  Google Scholar 

  13. Cheng GF, Brett ME, He B . Val(193) and Phe(195) of the gamma(1)34.5 protein of herpes simplex virus 1 are required for viral resistance to interferon-alpha/beta. Virology 2001; 290: 115–120.

    Article  CAS  Google Scholar 

  14. Leib DA, Machalek MA, Williams BR, Silverman RH, Virgin HW . Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc Natl Acad Sci USA 2000; 97: 6097–6101.

    Article  CAS  Google Scholar 

  15. Mohr S, Bakal C, Perrimon N . Genomic screening with RNAi: results and challenges. Annu Rev Biochem 2010; 11: 37–64.

    Article  Google Scholar 

  16. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK . RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011; 11: 59–67.

    Article  CAS  Google Scholar 

  17. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T et al. IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315–5320.

    CAS  Google Scholar 

  18. Lu QL, Abel P, Foster CS, Lalani EN . bcl-2: Role in epithelial differentiation and oncogenesis. Hum Pathol 1996; 27: 102–110.

    Article  CAS  Google Scholar 

  19. Albertson DG . Gene amplification in cancer. Trends Genet 2006; 22: 447–455.

    Article  CAS  Google Scholar 

  20. Shen W, Wang C-Y, Wang X-H, Fu Z-X . Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res 2009; 28: 81.

    Article  Google Scholar 

  21. Anesti A-M, Simpson GR, Price T, Pandha HS, Coffin RS . Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo. BMC Cancer 2010; 10: 486.

    Article  Google Scholar 

  22. Youle RJ, Strasser A . The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47–59.

    Article  CAS  Google Scholar 

  23. Yang J, Liu XS, Bhalla K, Kim CN, Ibrado AM, Cai JY et al. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129–1132.

    Article  CAS  Google Scholar 

  24. Lima RT, Martins SM, Guimaraes JE, Sambade C, Vasconcelos MH . Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 2004; 11: 309–316.

    Article  CAS  Google Scholar 

  25. Huang SL, Wu Y, Yu H, Zhang P, Zhang XQ, Ying L et al. Inhibition of Bcl-2 expression by a novel tumor-specific RNA interference system increases chemosensitivity to 5-fluorouracil in Hela cells. Acta Pharmacol Sin 2006; 27: 242–248.

    Article  CAS  Google Scholar 

  26. Kang MH, Reynolds CP . Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126–1132.

    Article  CAS  Google Scholar 

  27. Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC . Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 2011; 10: 35.

    Article  CAS  Google Scholar 

  28. Fukuda S, Pelus LM . Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006; 5: 1087–1098.

    Article  CAS  Google Scholar 

  29. Altieri DC . Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581–8589.

    Article  CAS  Google Scholar 

  30. Wang YH, Zhu HX, Quan LP, Zhou CQ, Bai JF, Zhang G et al. Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol Ther 2005; 4: 974–978.

    Article  CAS  Google Scholar 

  31. Croci DO, Cogno IS, Vittar NB, Salvatierra E, Trajtenberg F, Podhajcer OL et al. Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J Cell Biochem 2008; 105: 381–390.

    Article  CAS  Google Scholar 

  32. Liu Q, Fu H, Xing R, Tie Y, Zhu J, Sun Z et al. Survivin knockdown combined with apoptin overexpression inhibits cell growth significantly. Cancer Biol Ther 2008; 7: 1053–1060.

    Article  CAS  Google Scholar 

  33. Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y et al. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 68: 505–511.

    Article  CAS  Google Scholar 

  34. Dambach MJ, Trecki J, Martin N, Markovitz NS . Oncolytic viruses derived from the gamma 34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein. Mol Ther 2006; 13: 891–898.

    Article  CAS  Google Scholar 

  35. Carson J, Haddad D, Bressman M, Fong Y . Oncolytic herpes simplex virus 1 (HSV-1) vectors:increasing treatment efficacy and range through strategic virus design. Drugs Future 2010; 35: 183–195.

    Article  CAS  Google Scholar 

  36. Melcher A, Parato K, Rooney CM, Bell JC . Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011; 19: 1008–1016.

    Article  CAS  Google Scholar 

  37. Sartorius UA, Krammer PH . Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002; 97: 584–592.

    Article  CAS  Google Scholar 

  38. Adams JM, Cory S . The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324–1337.

    Article  CAS  Google Scholar 

  39. Altieri DC . Survivin and IAP proteins in cell-death mechanisms. Biochem J 2010; 430: 199–205.

    Article  CAS  Google Scholar 

  40. Markovic D, Dordevic V . Apoptosis regulation by inhibitors of programmed cell death. J Med Biochem 2013; 32: 207–213.

    Article  CAS  Google Scholar 

  41. Zachos G, Koffa M, Preston CM, Clements JB, Conner J . Herpes simplex virus type 1 blocks the apoptotic host cell defense mechanisms that target Bcl-2 and manipulates activation of p38 mitogen-activated protein kinase to improve viral replication. J Virol 2001; 75: 2710–2728.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Biomedical research institute, Beijing Normal University for providing the A549, SW480, HepG2 and Vero cell lines. This work was also supported by Beijing Source of God’s Biological Technology Co., Ltd.

Author information

Authors and Affiliations

  1. OrienGene Biotechnology Ltd, Beijing, P.R. China

    X Chen & J Wang

  2. Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry, College of Life Sciences, Beijing Normal University, Beijing, P.R. China

    X Chen, J Wang, J Yang, Y Zhai & B Li

  3. SinoGenoMax Co., Ltd./Chinese National Human Genome Center, Beijing, P.R. China

    Y Zhou & B Li

  4. Beijing Key Lab of Genomics, Beijing, P.R. China

    Y Zhou & B Li

Authors
  1. X Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y Zhai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Li.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, X., Zhou, Y., Wang, J. et al. Dual silencing of Bcl-2 and Survivin by HSV-1 vector shows better antitumor efficacy in higher PKR phosphorylation tumor cells in vitro and in vivo. Cancer Gene Ther 22, 380–386 (2015). https://doi.org/10.1038/cgt.2015.30

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2015.30

This article is cited by

Search

Advanced search

Quick links